Regeneron Pharmaceuticals, Inc. (REGN)
Company Info
Highlights
$61.69B
$39.33
14.53
1.24
$14.09B
$11.96B
$4.98B
$520.50 - $1,209.65
$797.21
2.82%
2.38
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Regeneron Pharmaceuticals, Inc. (REGN) returned -17.77% year-to-date (YTD) and -40.12% over the past 12 months. Over the past 10 years, REGN returned 1.67% annually, underperforming the S&P 500 benchmark at 10.79%.
REGN
-17.77%
4.85%
-25.15%
-40.12%
0.31%
1.67%
^GSPC (Benchmark)
0.60%
9.64%
-0.54%
11.47%
15.67%
10.79%
Monthly Returns
The table below presents the monthly returns of REGN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -5.52% | 3.96% | -9.23% | -5.59% | -2.30% | -17.77% | |||||||
| 2024 | 7.34% | 2.47% | -0.37% | -7.46% | 10.05% | 7.23% | 2.68% | 9.78% | -11.26% | -20.27% | -10.50% | -5.05% | -18.90% |
| 2023 | 5.13% | 0.26% | 8.05% | -2.42% | -8.26% | -2.31% | 3.25% | 11.40% | -0.43% | -5.23% | 5.63% | 6.61% | 21.73% |
| 2022 | -3.63% | 1.61% | 12.95% | -5.63% | 0.85% | -11.07% | -1.60% | -0.11% | 18.55% | 8.69% | 0.39% | -4.02% | 14.25% |
| 2021 | 4.29% | -10.57% | 5.01% | 1.72% | 4.39% | 11.17% | 2.88% | 17.19% | -10.13% | 5.74% | -0.53% | -0.79% | 30.72% |
| 2020 | -10.00% | 31.55% | 9.83% | 7.70% | 16.53% | 1.77% | 1.35% | -1.92% | -9.70% | -2.90% | -5.06% | -6.38% | 28.66% |
| 2019 | 14.93% | 0.34% | -4.67% | -16.43% | -12.07% | 3.74% | -2.63% | -4.83% | -4.36% | 10.41% | 20.48% | 1.76% | 0.53% |
| 2018 | -2.48% | -12.60% | 7.46% | -11.81% | -1.11% | 14.87% | 6.67% | 10.53% | -0.67% | -16.04% | 7.79% | 2.15% | -0.65% |
| 2017 | -2.12% | 3.96% | 3.75% | 0.25% | 18.17% | 6.99% | 0.10% | 1.07% | -10.02% | -9.95% | -10.12% | 3.90% | 2.42% |
| 2016 | -22.62% | -8.59% | -6.14% | 4.51% | 5.90% | -12.46% | 21.73% | -7.66% | 2.41% | -14.18% | 9.92% | -3.20% | -32.38% |
| 2015 | 1.56% | -0.68% | 9.10% | 1.32% | 12.04% | -0.47% | 8.53% | -7.25% | -9.42% | 19.83% | -2.31% | -0.30% | 32.33% |
| 2014 | 4.85% | 15.22% | -9.69% | -1.13% | 3.39% | -7.98% | 11.95% | 10.83% | 2.87% | 9.21% | 5.69% | -1.41% | 49.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of REGN is 6, meaning it’s performing worse than 94% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Regeneron Pharmaceuticals, Inc. provided a 0.15% dividend yield over the last twelve months, with an annual payout of $0.88 per share.
| Period | TTM |
|---|---|
| Dividend | $0.88 |
Dividend yield | 0.15% |
Monthly Dividends
The table displays the monthly dividend distributions for Regeneron Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.88 | $0.00 | $0.00 | $0.00 | $0.88 |
Dividend Yield & Payout
Dividend Yield
Regeneron Pharmaceuticals, Inc. has a dividend yield of 0.15%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Regeneron Pharmaceuticals, Inc. has a payout ratio of 3.97%, which is below the market average. This means Regeneron Pharmaceuticals, Inc. returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Regeneron Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Regeneron Pharmaceuticals, Inc. was 91.81%, occurring on Apr 14, 2005. Recovery took 1520 trading sessions.
The current Regeneron Pharmaceuticals, Inc. drawdown is 51.26%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.81% | Mar 1, 2000 | 1287 | Apr 14, 2005 | 1520 | Apr 27, 2011 | 2807 |
| -86.67% | Feb 7, 1992 | 733 | Dec 30, 1994 | 446 | Oct 4, 1996 | 1179 |
| -77.41% | Oct 9, 1996 | 628 | Apr 7, 1999 | 223 | Feb 23, 2000 | 851 |
| -56.03% | Aug 28, 2024 | 175 | May 9, 2025 | — | — | — |
| -53.84% | Aug 6, 2015 | 1044 | Sep 27, 2019 | 168 | May 29, 2020 | 1212 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Regeneron Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Regeneron Pharmaceuticals, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -3.0%.
Valuation
The Valuation section provides an overview of how Regeneron Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for REGN, comparing it with other companies in the Biotechnology industry. Currently, REGN has a P/E ratio of 14.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for REGN compared to other companies in the Biotechnology industry. REGN currently has a PEG ratio of 1.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for REGN relative to other companies in the Biotechnology industry. Currently, REGN has a P/S ratio of 4.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for REGN in comparison with other companies in the Biotechnology industry. Currently, REGN has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |